← Back to Search

Corticosteroid

Treatment for Multiple Myeloma (sEAPort Trial)

N/A
Waitlist Available
Research Sponsored by Oncopeptides AB
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

sEAPort Trial Summary

To provide early treatment access and evaluate the safety of melflufen and dexamethasone in patients with triple class refractory (TCR) multiple myeloma (MM).

Eligible Conditions
  • Multiple Myeloma

sEAPort Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Find a Location

Who is running the clinical trial?

Oncopeptides ABLead Sponsor
9 Previous Clinical Trials
905 Total Patients Enrolled
7 Trials studying Multiple Myeloma
872 Patients Enrolled for Multiple Myeloma
~233 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top